ReviewCancer science2026
Advances in the Role of Chemokines in Microwave Ablation-Based Combinatorial Immunotherapy.
Review in Cancer science, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Immunotherapy enhances antitumor immunity to eliminate malignant cells and has great potential to prevent tumor recurrence and distant metastasis. In addition to direct tumor destruction, microwave ablation (MWA) remodels the tumor immune microenvironment (TIME) and induces antitumor immune responses, providing a strong rationale for combination with immunotherapy. As key regulators of immune-cell trafficking and function, chemokines critically mediate the synergy between MWA and immunotherapy. In this review, we summarize the effects of MWA on the TIME, the central role of chemokine networks in this process, and recent advances in MWA-based combinatorial immunotherapy, including clinical progress. We also discuss current challenges and future directions to support the optimization of multimodal cancer therapy and improve clinical outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.